International Clinical Psychopharmacology (original) (raw)

The editors of this journal are pleased to offer electronic publication of accepted papers prior to issue publication. These papers can be cited using the date of access and the unique DOI number. Any final changes in manuscripts will be made at the time of issue publication and will be reflected in the final electronic version of the issue.

Disclaimer: Articles appearing in this Latest Articles section have been peer-reviewed and accepted for publication in this journal and posted online before issue publication. Articles appearing here may contain statements, opinions, and information that have errors in facts, figures, or interpretation. Accordingly, Wolters Kluwer, the editors and authors and their respective employees are not responsible or liable for the use of any such inaccurate or misleading data, opinion or information contained the articles in this section.

Case report

Aripiprazole‑induced akathisia associated with bilateral putaminal hypermetabolism on PET

Meda, Nicola; Lussignoli, Marialaura; Gugliotta, Alessio A.; Cecchin, Diego; Pigato, Giorgio; Sambataro, Fabio Less

April 14, 2026

Plain Language Summary This case report describes a woman in her 50s with bipolar disorder and autoimmune diseases who developed marked akathisia after lithium was augmented with aripiprazole 10 mg/day. During symptomatic akathisia, a whole-body [18F]FDG PET computed tomography, ordered for recurrent fevers and gastrointestinal symptoms, incidentally showed bilateral putaminal hypermetabolism relative to the cerebral cortex. Neurological and rheumatology evaluations were negative, and no other medications were changed. Akathisia resolved completely after aripiprazole discontinuation and clonazepam up-titration, and the Naranjo Adverse Drug Reaction Probability Scale indicated a probable adverse drug reaction. This observation suggests basal ganglia hypermetabolism may be linked to aripiprazole-induced akathisia and warrants confirmation in prospective studies.

Text is machine generated and may contain inaccuracies. FAQ

Original research article

Defining treatment-resistant depression in a real-world setting: impact of a staging model on clinical features and treatment trajectories

Carminati, Matteo; Tondello, Mattia; Morana, Chiara; More

Carminati, Matteo; Tondello, Mattia; Morana, Chiara; Serretti, Alessandro; Zanardi, Raffella Less

March 26, 2026

Plain Language Summary This study examined how a simple two-stage model of treatment-resistant depression (TRD) works in routine inpatient care. Among 538 depressed inpatients, patients were classified as nonresistant, TRD1 (≥2 antidepressant failures at minimally licensed dose for ≥4 weeks), or TRD2 (≥2 failures from different classes at maximum tolerated dose for ≥4 weeks). TRD1 patients (24%) had earlier onset and more personality disorders, anxiety disorders, tobacco smoking, AUD, and substance use disorder, yet showed good symptom improvement. TRD2 patients (29%) had more severe, longer episodes, needed more intensive treatments, and showed significantly reduced improvement over 8 weeks, suggesting a more biologically refractory profile and supporting graded TRD definitions for tailored management.

Text is machine generated and may contain inaccuracies. FAQ

Original research article

Association between the number of delirium-associated medications and postoperative delirium in older adults: a multicenter retrospective study

Hatano, Masakazu; Sogawa, Rintaro; Araki, Haruna; More

Hatano, Masakazu; Sogawa, Rintaro; Araki, Haruna; Matsumura, Toshiki; Esumi, Satoru; Shin, Kenji; Tabuchi, Hironori; Tsubouchi, Kiyotaka; Ozaki, Taisuke; Kamei, Hiroyuki; Suga, Kensuke; Okochi, Tomo; Yamada, Shigeki Less

March 26, 2026

Plain Language Summary This multicenter retrospective study examined whether taking more types of delirium-associated medications increases the risk of postoperative delirium (POD) in older adults. It included 4562 patients aged ≥70 years who had surgery under general anesthesia. Seven medication classes were assessed: benzodiazepines, non-benzodiazepines, opioids, antiparkinsonian agents, glucocorticoids, H1-antihistamines, and H2-antihistamines. Overall, 7.7% (352/4562) developed POD, rising from 6.0% in patients receiving none of these medications to 31.0% in those receiving four or more types. Multivariate logistic regression showed higher odds ratios for POD as the number of medication types increased. Sensitivity analyses supported these results, highlighting the importance of preoperative medication review in this population.

Text is machine generated and may contain inaccuracies. FAQ

Research article

Preliminary evidence that blood extracellular nicotinamide phosphoribosyltransferase increases with antidepressant response to chronotherapeutics and to monoaminergic drugs

Benedetti, Francesco; Branchi, Igor; Shin, Ha Kyung; More

Benedetti, Francesco; Branchi, Igor; Shin, Ha Kyung; Lorenzi, Cristina; Venturelli, Edoardo; Dallaspezia, Sara; Colombo, Cristina; Zanardi, Raffaella; Poletti, Sara Less

March 11, 2026

Plain Language Summary This study explored the role of extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in the effectiveness of antidepressant treatments. Researchers measured eNAMPT levels in 46 patients with major depressive disorder or bipolar disorder before and after treatment. They found that an increase in eNAMPT was linked to better treatment outcomes, regardless of the type of antidepressant used. However, not all patients needed an eNAMPT increase to benefit from treatment. These results suggest eNAMPT might enhance treatment efficacy rather than directly reduce symptoms, supporting the idea that NAD+ homeostasis and mitochondrial function are important in mood disorders. This could lead to new depression treatments.

Text is machine generated and may contain inaccuracies. FAQ

Case report

Samidorphan sadness: does the addition of samidorphan to olanzapine have prodepressive effects?

Parkerson, Jamie A.; Chaia, Angelo I.; Lynch, Sean T.; More

Parkerson, Jamie A.; Chaia, Angelo I.; Lynch, Sean T.; Sterchele, Ashley N. Less

February 26, 2026

Plain Language Summary Olanzapine–samidorphan (Lybalvi) is a medication combining olanzapine with samidorphan to reduce weight gain associated with olanzapine. While effective in clinical trials, mood effects are less understood. A case study of a 40-year-old man showed significant depressive symptoms after switching from olanzapine alone to olanzapine–samidorphan. Symptoms resolved when he returned to olanzapine monotherapy, suggesting a possible link to samidorphan. Samidorphan's action on opioid receptors might cause mood changes, as κ-receptor activation is associated with dysphoria. Although large studies haven't shown consistent mood effects, individual differences may exist. This case underscores the need for monitoring mood changes in patients using olanzapine–samidorphan.

Text is machine generated and may contain inaccuracies. FAQ

Original research article

Long-acting injectable vs. oral antipsychotics during electroconvulsive therapy in psychosis: a retrospective comparative study

Jeong, Hee Won; Kim, Yong Sik; Kim, Eui-Joong; More

Jeong, Hee Won; Kim, Yong Sik; Kim, Eui-Joong; Bhang, Soo-Young; Choi, Jae-Won; Jeong, Jae Hoon; Kang, Hyoseok; Lee, Kyu Young Less

February 26, 2026

Plain Language Summary This study explored the effectiveness of long-acting injectable (LAI) antipsychotics compared to oral antipsychotics in patients with psychosis undergoing electroconvulsive therapy (ECT). By reviewing medical records of 65 patients, researchers found that those receiving LAI antipsychotics during ECT had a higher treatment response rate (72.7%) than those on oral antipsychotics (37.5%). Additionally, LAI antipsychotics were linked to greater symptom improvement, particularly in negative and general psychopathology symptoms, as measured by the Positive and Negative Syndrome Scale (PANSS). These results suggest that LAI antipsychotics may enhance clinical outcomes during ECT, but further research is needed to confirm these findings.

Text is machine generated and may contain inaccuracies. FAQ

Original research article

Sogawa, Rintaro; Uno, Junji; Yoshimi, Akira; More

Sogawa, Rintaro; Uno, Junji; Yoshimi, Akira; Umeda, Kenta; Uekusa, Shusuke; Kobayashi, Mami; Tokizaki, Michinori; Tensho, Masami; Yoshio, Takashi; Inada, Toshiya; Shimanoe, Chisato; Kurosawa, Masahiro; Psychiatric Clinical Pharmacy Research Group Less

February 18, 2026

Plain Language Summary A survey in Japan studied antipsychotic polypharmacy (APP) among 3657 outpatients with schizophrenia, revealing that 40.8% were on multiple antipsychotics despite monotherapy being preferred. APP was linked to male sex, older age, use of long-acting injectables, and additional medications like antiparkinsonian agents, anxiolytics, and mood stabilizers. Conversely, clozapine use was less common in APP. Antipsychotic doses, standardized to chlorpromazine equivalents, were highest in patients aged 40-59. Second-generation antipsychotics were most used, but first-generation use rose with polypharmacy. These results highlight the need for careful APP management, considering sex and age in prescribing practices.

Text is machine generated and may contain inaccuracies. FAQ

Original research article

Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressants

Guidetti, Clotilde; Papakostas, George I.; Stahl, Steven; More

Guidetti, Clotilde; Papakostas, George I.; Stahl, Steven; Pani, Luca; De Martin, Sara; Mattarei, Andrea; Comai, Stefano; Kröger, Cornelia; Champasa, Paggard; Gorodetzky, Charles W.; Vocci, Frank J.; Kosten, Thomas R.; Bushnell, David; Kappler, Martin; Folli, Franco; Inturrisi, Charles E.; Pappagallo, Marco; Manfredi, Paolo L.; Fava, Maurizio Less

February 17, 2026

Plain Language Summary Esmethadone is being tested as an additional treatment for major depressive disorder in patients who don't respond well to standard antidepressants. In a phase 3 study, esmethadone didn't achieve the main goal of improving depression scores by day 28, but it did show significant improvement in response rates. Further analysis suggested that esmethadone might be effective for patients with severe depression, indicated by a baseline score of 35 or higher on the Montgomery–Åsberg Depression Rating Scale. Sensitivity analyses confirmed larger treatment effects in patients with higher baseline severity, supporting esmethadone's potential efficacy in severe cases.

Text is machine generated and may contain inaccuracies. FAQ

Original research article

Risperidone- and paliperidone-induced hyperprolactinemia in routine clinical practice: demographic and pharmacological determinants from the UAE

Aly El-Gabry, Dina; Mohd Ahmed, Hind; Andrade, Gabriel; More

Aly El-Gabry, Dina; Mohd Ahmed, Hind; Andrade, Gabriel; Reddy, Marri Subhash; Abdel Aziz, Karim; Alkharoossi, Amani; Alkaabi, Alyazia Abdulla; Al Ketbi, Jamila; Omara, Anne Elzein; Al Ahbabi, Mohammed; Al Ahbabi, Noura; Javaid, Syed Fahad; Amiri, Leena; Barakat, Doaa Helmy; Al Sabousi, Mouza; Stip, Emmanuel Less

February 16, 2026

Plain Language Summary This study examined antipsychotic-induced hyperprolactinemia in a large cohort from the UAE, focusing on patients with schizophrenia treated with risperidone or paliperidone. Among 835 patients, 61.9% had elevated prolactin levels, with the highest levels in those taking oral paliperidone. Younger age, female gender, non-Emirati nationality, paliperidone use, and aripiprazole cotreatment were predictors of hyperprolactinemia. Sexual side effects were reported in 9.2% of patients but were often under-recognized. The findings highlight the importance of regular endocrine monitoring and tailored prescribing practices to reduce polypharmacy and address specific needs in the UAE and Gulf region.

Text is machine generated and may contain inaccuracies. FAQ

Original research article

An observational study on the effects of as-needed use of various antipsychotic drugs for agitation due to psychotic disorders

Hatta, Kotaro; Morikawa, Fumiyoshi; Yamasaki, Satoshi; More

Hatta, Kotaro; Morikawa, Fumiyoshi; Yamasaki, Satoshi; Ishizuka, Takuya; Nakamura, Mitsuru; Hino, Kosuke; Katayama, Shigemasa; Imai, Atsushi; Fujita, Kiyoshi; Sugiyama, Naoya; for the JAST study group Less

January 15, 2026

Plain Language Summary This study looked at how quickly different psychotropic medications calm patients with acute psychotic disorders. It found that oral and sublingual medications like asenapine and olanzapine have varying onset times, with asenapine working faster than quetiapine and risperidone. Injectable medications like olanzapine and haloperidol had similar onset times, but patients often refused injectable formulations. Asenapine sublingual had the quickest calming effect, with a mean onset time of 30 minutes. No serious side effects were reported. The study suggests that asenapine sublingual might be a better option for quick calming, but more research is needed to confirm these findings with shorter assessment intervals.

Text is machine generated and may contain inaccuracies. FAQ